Literature DB >> 27959622

DWI for Assessment of Rectal Cancer Nodes After Chemoradiotherapy: Is the Absence of Nodes at DWI Proof of a Negative Nodal Status?

Miriam M van Heeswijk1,2,3, Doenja M J Lambregts2, Walter M Palm3, Babs M F Hendriks3, Monique Maas2,3, Geerard L Beets1,4, Regina G H Beets-Tan1,2.   

Abstract

OBJECTIVE: When considering organ preservation in patients with rectal cancer with good tumor response, assessment of a node-negative status after chemoradiation therapy (CRT) is important. DWI is a very sensitive technique to detect nodes. The study aim was to test the hypothesis that the absence of nodes at DWI after CRT is concordant with a ypN0 status.
MATERIALS AND METHODS: A retrospective study was performed of 90 patients with rectal cancer treated with CRT followed by restaging MRI at 1.5 T, including DWI (highest b value, 1000 s/mm2). Two independent readers counted the number of nodes visible in the mesorectal compartment on DW images obtained after CRT. The number of nodes on DWI (0 vs ≥ 1) was compared with the number of metastatic nodes at histopathology or long-term clinical follow-up (yN0 vs yN-positive status).
RESULTS: Seventy-one patients had a yN0 status, and 19 had a yN-positive status. For 10 patients, no nodes were observed at DWI, which was concordant with a yN0 status in 100% of cases. In the other 61 patients with a yN0 status, the median number of nodes detected at DWI was three (range, 1-17 nodes). To differentiate between yN0 and yN-positive status, sensitivity was 100%, specificity was 14%, the positive predictive value was 24%, and the negative predictive value was 100%.
CONCLUSION: Although the absence of nodes at DWI is not a frequent finding, it appears to be a reliable predictor of yN0 status after CRT in patients with rectal cancer. DWI may thus be a helpful adjunct in assessing response after CRT and may help select patients for organ-saving treatment.

Entities:  

Keywords:  DWI; locally advanced rectal cancer; lymph node staging; nodal restaging; organ preservation

Mesh:

Year:  2016        PMID: 27959622     DOI: 10.2214/AJR.16.17117

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

Review 1.  Lateral Pelvic Lymph Node Metastases in Rectal Cancer: A Systematic Review.

Authors:  Y Atef; T W Koedam; S E van Oostendorp; H J Bonjer; A R Wijsmuller; J B Tuynman
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

Review 2.  Diffusion-weighted imaging in rectal cancer: current applications and future perspectives.

Authors:  Niels W Schurink; Doenja M J Lambregts; Regina G H Beets-Tan
Journal:  Br J Radiol       Date:  2019-03-05       Impact factor: 3.039

Review 3.  MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management.

Authors:  Natally Horvat; Camila Carlos Tavares Rocha; Brunna Clemente Oliveira; Iva Petkovska; Marc J Gollub
Journal:  Radiographics       Date:  2019-02-15       Impact factor: 5.333

4.  Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer.

Authors:  Per Loftås; Margrét Sturludóttir; Olof Hallböök; Karin Almlöv; Gunnar Arbman; Lennart Blomqvist
Journal:  Br J Radiol       Date:  2018-05-10       Impact factor: 3.039

Review 5.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

Review 6.  The importance of MRI for rectal cancer evaluation.

Authors:  Maria Clara Fernandes; Marc J Gollub; Gina Brown
Journal:  Surg Oncol       Date:  2022-03-18       Impact factor: 2.388

Review 7.  Rectal cancer MRI: protocols, signs and future perspectives radiologists should consider in everyday clinical practice.

Authors:  Andrea Delli Pizzi; Raffaella Basilico; Roberta Cianci; Barbara Seccia; Mauro Timpani; Alessandra Tavoletta; Daniele Caposiena; Barbara Faricelli; Daniela Gabrielli; Massimo Caulo
Journal:  Insights Imaging       Date:  2018-04-19

8.  Nomograms and risk score models for predicting survival in rectal cancer patients with neoadjuvant therapy.

Authors:  Fang-Ze Wei; Shi-Wen Mei; Jia-Nan Chen; Zhi-Jie Wang; Hai-Yu Shen; Juan Li; Fu-Qiang Zhao; Zheng Liu; Qian Liu
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

9.  Radiological assessment of persistent retroperitoneal and lateral pelvic lymph nodes after neoadjuvant therapy for rectal cancer: An analysis of the United States Rectal Cancer Consortium.

Authors:  Michael K Turgeon; Adriana C Gamboa; Jessica M Keilson; Jeffrey Maniko; Lillias Maguire; Katherine Hrebinko; Jennifer Holder-Murray; Jason T Wiseman; Sherif Abdel-Misih; Saif Hamdan; Alexander T Hawkins; Philip Bauer; Matthew Silviera; Shishir K Maithel; Glen C Balch
Journal:  J Surg Oncol       Date:  2021-07-16       Impact factor: 2.885

10.  Diffusion-weighted MRI in the evaluation of the thyroid nodule: Comparison between integrated-shimming EPI and conventional 3D-shimming EPI techniques.

Authors:  Luguang Chen; Peipei Sun; Qiang Hao; Wei Yin; Bing Xu; Chao Ma; Alto Stemmer; Caixia Fu; Minjie Wang; Jianping Lu
Journal:  Oncotarget       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.